Anagrelide(简称ANA)是一种新的具有抗血小板聚集作用的降血小板药。本文评价ANA对慢性骨髓增生症伴显著血小板增多病人的疗效。 20例血小板增多病人参加研究,最初口服剂量均为2mg,每6小时1次,以后根据血小板计数调整剂量。研究期间,每周测全血细胞计数3次。8例病人在给药前和血小板增多被控制后分别进行骨髓形态学检查。结果:口服ANA初剂量后可见绝大数病人的血小板降低。通常口服ANA 5天后血 Anagrelide (ANA) is a new antiplatelet agent with anti-platelet aggregation effect. This article evaluates the efficacy of ANA in patients with chronic myeloproliferative disorders with significant thrombocytosis. Twenty patients with thrombocytosis participated in the study. Initial oral doses were both 2 mg once every 6 hours and later adjusted to the platelet count. During the study, the whole blood count was measured three times a week. Eight patients underwent bone marrow morphological examination before administration and after thrombocytosis was controlled. Results: The initial dose of oral ANA shows the vast majority of patients with thrombocytopenia. ANA 5 days after oral administration of blood